Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Cornea ; 40(10): 1340-1343, 2021 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-34481411

RESUMO

PURPOSE: To report the clinical and confocal findings of a unique case of combined Phialemonium curvatum and Acanthamoeba keratitis and to highlight the role of the prompt diagnosis and specific medical treatment in preserving visual function. METHODS: A case report and literature review. RESULTS: A 54-year-old woman presented with a 3-day history of visual impairment, photophobia, and ocular pain in her right eye. Her best corrected visual acuity was 0.4 Logarithm of the Minimum Angle of Resolution scale, and the slit-lamp examination showed whitish corneal stromal infiltrate with satellite lesions. In vivo confocal microscopy evidenced Acanthamoeba cysts and fungal hyphae that resulted P. curvatum in the culture examination. The intensive medical treatment was started with topical 0.02% polyhexamethylene biguanide, voriconazole 1%, and moxifloxacin hydrochloride 0.5%. Progressive improvement of clinical and confocal pictures was registered with a complete recovery of visual function after 1 month. CONCLUSIONS: This is the first case report of combined P. curvatum and Acanthamoeba keratitis. The fast diagnosis with in vivo confocal microscopy allowed early and intensive specific treatment with recovery of corneal infection.


Assuntos
Ceratite por Acanthamoeba/diagnóstico , Ascomicetos/isolamento & purificação , Infecções Oculares Fúngicas/diagnóstico , Ceratite/diagnóstico , Micoses/diagnóstico , Ceratite por Acanthamoeba/tratamento farmacológico , Ceratite por Acanthamoeba/parasitologia , Administração Oftálmica , Antibacterianos/uso terapêutico , Antifúngicos/uso terapêutico , Biguanidas/uso terapêutico , Desinfetantes/uso terapêutico , Quimioterapia Combinada , Diagnóstico Precoce , Infecções Oculares Fúngicas/tratamento farmacológico , Infecções Oculares Fúngicas/microbiologia , Feminino , Humanos , Ceratite/tratamento farmacológico , Ceratite/microbiologia , Microscopia Confocal , Pessoa de Meia-Idade , Moxifloxacina/uso terapêutico , Micoses/tratamento farmacológico , Micoses/microbiologia , Soluções Oftálmicas , Microscopia com Lâmpada de Fenda , Voriconazol/uso terapêutico
2.
Eur J Ophthalmol ; 28(1): 25-31, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-28777385

RESUMO

PURPOSE: Dry eye disease (DED) is a common condition causing substantial burden. A randomized, controlled, single-masked study was performed in 40 patients with mild to moderate DED to evaluate the efficacy and safety of a collyrium based on crosslinked hyaluronic acid (XLHA) with coenzyme Q10 (CoQ10). METHODS: Enrolled subjects were divided into 2 groups: group A, treated with XLHA + CoQ10; and group B, treated with hyaluronic acid (HA). Eyedrops were administered 4 times daily for 3 months. The Ocular Surface Disease Index (OSDI) questionnaire, tear break-up time (TBUT), corneal and conjunctival staining, and meibomian gland assessment (MGD) were evaluated; furthermore, corneal aesthesiometry, in vivo corneal confocal microscopy, visual acuity, intraocular pressure (IOP), and fundus examination were performed. RESULTS: At the end of treatment, OSDI score significantly decreased in groups A and B (p<0.01 and p<0.05, respectively); the decrease was significantly higher in group A. Corneal staining decreased in both groups, with lower scores in group A. The MGD was significantly ameliorated in group A patients. No differences were found for corneal aesthesiometry or TBUT. Epithelial cell reflectivity was significantly reduced only in group A. For keratocytes and stromal matrix parameters, there was a significant improvement in group A. No changes were found for visual acuity, IOP, or fundus examination. CONCLUSIONS: The XLHA + CoQ10 treatment showed greater effectiveness in DED compared to HA alone, probably due to the longer permanency on ocular surface and the antioxidant activity of CoQ10. Therefore, XLHA + CoQ10 eyedrops could represent a new possibility in dry eye treatment.


Assuntos
Reagentes de Ligações Cruzadas/administração & dosagem , Síndromes do Olho Seco/tratamento farmacológico , Ácido Hialurônico/administração & dosagem , Ubiquinona/análogos & derivados , Acuidade Visual , Adjuvantes Imunológicos/administração & dosagem , Córnea/efeitos dos fármacos , Córnea/metabolismo , Córnea/patologia , Relação Dose-Resposta a Droga , Quimioterapia Combinada , Síndromes do Olho Seco/diagnóstico , Síndromes do Olho Seco/fisiopatologia , Feminino , Seguimentos , Humanos , Masculino , Microscopia Confocal , Pessoa de Meia-Idade , Soluções Oftálmicas/administração & dosagem , Método Simples-Cego , Resultado do Tratamento , Ubiquinona/administração & dosagem , Vitaminas/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA